A recent notification of the Union government stated that companies importing or exporting human biological samples for commercial or research purposes would not require import licences or export permits.
While the industry welcomed the move, some said this notification was just doing away with the paperwork. Revenues won't be impacted drastically, nor would it increase the number of samples into the country.
Also Read
In an e-mail response to a query on the subject, Dr N Sathyabhama, director of Medical Services and Quality, southern region, Apollo Hospitals Enterprise Limited, said, "The policy will ensure quick and hassle-free processing of critical diagnostic samples and help patients get a treatment plan at the earliest."
Another industry source told Business Standard this notification would make companies more responsible because the onus will be on them to abide by the rules.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)